Abstract:Backgrounds: Epidermal growth factor receptor (EGFR) mutation profiles play a vital role in treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this study was to evaluate the predictive efficacy of baseline 18 F-FDG PET/CT-based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of targeted therapy. Methods: A sum of 313 NSCLC patients with pre-treatment 18 F-FDG PET/CT scans and genetic mutations detection were retrospectively studied. Clinical and PET metabolic parameters were incorporated into independent predictors of determining mutation status and mutation site. The dataset was randomly allocated into the training and the validation sets in a 7:3 ratio. Three-dimensional (3D) radiomics features were extracted from each PET- and CT-volume of interests (VOI) singularly, and then a radiomics signature (RS) associated with EGFR mutation profiles is built by feature selection. Three different prediction models based on support vector machine (SVM), decision tree (DT), and random forest (RF) classifiers were established. Furthermore, nomograms for estimation of overall survival (OS) and progression-free survival (PFS) were established by integrating PET/CT radiomics score (Rad-score), metabolic parameters, and clinical factors. Predictive performance was assessed by the receiver operating characteristic (ROC) analysis and the calibration curve analysis. The decision curve analysis (DCA) was applied to estimate and compare the clinical usefulness of nomograms. Results: Three hundred thirteen NSCLC patients were classified into a training set (n=218) and a validation set (n=95). Multivariate analysis demonstrated that SUVmax and sex were independent indicators of EGFR mutation status and mutation site. Eight CT-derived RS, six PET-derived RS, and two clinical factors were retained to develop integrated models, which exhibited excellent ability to distinguish between EGFR wild type (EGFR-WT), EGFR 19 mutation type (EGFR-19-MT), and EGFR 21 mutation type (EGFR-21-MT). The SVM model outperformed the RF model and the DT model, yielding training area under the curves (AUC) of EGFR-WT, EGFR-19-WT, and EGFR-21-WT, with 0.881, 0.851, and 0.849, respectively, and validation AUCs of 0.926, 0.805 and 0.859, respectively. For prediction of OS, the integrated nomogram is superior to the clinical nomogram and the radiomics nomogram, with C-indexes of 0.80 in the training set and 0.83 in the validation set, respectively. Conclusions: The PET/CT-based radiomics analysis might provide a novel approach to predict EGFR mutation status and mutation site in NSCLC patients and could serve as useful predictors for the patients' survival outcome of targeted therapy in clinical practice.

The Correlation of Mutation Status of EGFR and KRAS with SUVmax of 18F-FDG-PET/CT in Non-Small-cell Lung-Cancer

Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag

Association Analysis of Maximum Standardized Uptake Values Based on 18F-FDG PET/CT and EGFR Mutation Status in Lung Adenocarcinoma

Correlation of FDG PET/CT, tumor markers and Ki-67 index with EGFR mutation or positive ALK expression in patients with non-small cell lung cancer

Predictive Value Of Suvmax Measured By F-18-Fdg Pet/Ct In Patients With Early Stage Non-Small Cell Lung Cancer

Correlations Study Between 18 F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma.

Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

CT-based non-invasive identification of the most common gene mutation status in patients with non-small cell lung cancer

The relationship between clinical and pathological findings and FDG - PET uptake in metastatic colorectal cancers

Primary metabolic tumor volume from <SUP>18</SUP>F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients

Association Between Histopathological Subtype, 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.

Cross-sectional imaging utilization for EGFR, EML/ALK, and KRAS mutant non-small cell lung cancer.

FDG PET-CT in non-small cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential.

[Primary Tumor SUVmax Measured on (18)F-FDG PET-CT Correlates with Histologic Grade and Pathologic Stage in Non-Small Cell Lung Cancer].

Prognostic Value of 2-[18F]fluoro-2-deoxy-d-glucose Uptake As Measured by PET Scan in Patients with Non-Small Cell Lung Cancer.

Prognostic Value of the Standardized Uptake Value Maximum Change Calculated by Dual-Time-point (18)F-Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients with Advanced Non-Small-cell Lung Cancer.

Prognostic value of SUVmax for locally advanced non-small cell lung cancer patients treated with synchronous cetuximab plus concurrent chemoradiotherapy

EGFR mutation prediction using F18-FDG PET-CT based radiomics features in non-small cell lung cancer

The Effect of Standardized Uptake Value of ~(18)F-FDG-PET on Prognosis of Non-small Cell Lung Cancer

Incorporation of the SUVmax Measured from FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients with Locally Advanced Non–small-cell Lung Cancer